CD274 and hepatocellular carcinoma: Subsequently, the IMbrave150 trial, a global phase III trial, revealed that both the overall survival (OS) rates and progression-free survival (PFS) rates in MTA-naïve patients with advanced HCC were significantly higher in those receiving combining immunotherapy plus chemotherapy with atezolizumab and bevacizumab (monoclonal antibodies binding to programmed cell death 1-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF)-A, respectively) than in those receiving chemotherapy with sorafenib alone [3].